Loading organizations...
Hy2Care develops the CartRevive hydrogel implant, designed for functional recovery of joint cartilage defects. This innovative hydrogel employs joint-tissue mimicking natural polymers, creating a scaffold that encourages a patient's cells to deposit new cartilage matrix. The system protects injured sites and facilitates the body's natural repair mechanisms.
Established in 2014, the company emerged as a spin-off from the Tech Med Centre at the University of Twente, Netherlands. Co-founders Prof. Marcel Karperien and Dr. Sanne Both remain involved. Dr. Both's personal experience with cartilage defects provided foundational insight, driving development of a durable solution to this widespread medical challenge.
Hy2Care targets millions suffering traumatic cartilage defects, seeking faster healing, pain relief, and a return to full activity. The product endeavors to prevent the onset of post-traumatic osteoarthritis. The company's vision centers on enabling inherent biological repair, reducing chronic pain and the necessity for repeat interventions.
Hy2Care has raised $9.0M across 2 funding rounds.
Hy2Care has raised $9.0M in total across 2 funding rounds.
Hy2Care has raised $9.0M across 2 funding rounds. Most recently, it raised $5.0M Series U in May 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2025 | $5M Series U | — | Brightlands Venture Partners, JON Moulton | Announced |
| Apr 1, 2019 | $4M Series A | — | Brightlands Venture Partners, JON Moulton | Announced |
Hy2Care has raised $9.0M in total across 2 funding rounds.
Hy2Care's investors include Brightlands Venture Partners, Jon Moulton.
Hy2Care is a Dutch biomedical spin‑off that develops an *in situ* gelating, bioresorbable hydrogel implant (CartRevive®) designed to repair traumatic cartilage defects and promote true cartilage regeneration rather than scar tissue formation[6][1]. Hy2Care’s technology aims to offer a minimally invasive, arthroscopic treatment that adheres to surrounding cartilage and is resorbed as native tissue integrates, with clinical programs progressing in Europe and the U.S.[6][1].
High‑level overview
Origin story
Core differentiators
Role in the broader tech and healthcare landscape
Quick take & future outlook
Overall, Hy2Care presents a scientifically grounded, minimally invasive hydrogel approach aimed at restoring true cartilage rather than managing symptoms, and 2024–2026 clinical and regulatory milestones will determine whether it becomes a transformative option in joint preservation[6][1].